W_pro1 cancer vaccine

A messenger ribonucleic acid (mRNA)-based cancer vaccine that encodes five prostate cancer-selective off-the-shelf shared antigens that are separately complexed with liposomes to form serum-stable RNA lipoplexes (RNA-LPX), with potential immunomodulating and antineoplastic activities. Upon intravenous administration of the W_pro1 cancer vaccine, the RNA-LPX are taken up by antigen-presenting cells (APCs), especially dendritic cells (DCs). Upon uptake, the antigens are translated, processed, and presented to the immune system on major histocompatibility complex (MHC) class I and II molecules. This may activate the immune system to induce both an adaptive and innate immune response against cancer cells expressing these five antigens.